Healthcare Industry News: HSMN NewsFeed
News Release - February 28, 2018
SnoreRx, Now Available at CVS, is First and Only FDA Certified Non-prescription Anti Snoring TreatmentALISO VIEJO, Calif., Feb. 28, 2018 -- (Healthcare Sales & Marketing Network) -- Apnea Sciences Corporation announced that SnoreRx is now available at selected CVS pharmacies. FDA has recently cleared SnoreRx as the first and only oral appliance for the treatment of snoring without prescription.
No woman need suffer any longer with their husband's snoring. The treatment is simple, painless, low cost and 100% guaranteed to work! SnoreRx's six year track record of clinical effectiveness and safety qualified it as Best in Class. The American Sleep Association rates SnoreRx as #1, with 5 stars! https://www.sleepassociation.org/top-anti-snoring-mouthpieces-mouth-guards-reviews/
SnoreRx is an oral appliance that works by maintaining an open airway while you sleep by slightly advancing your lower jaw. Its patented Micro-Fit feature offers adjustment in 1mm increments allowing each patient to select the optimal comfort setting.
Finally, a safe and clinical effective method to treat his snoring!
James Fallon, President said, "This FDA certification of SnoreRx communicates to consumers that our product meets and exceeds all FDA standards. That is why CVS has elected to offer SnoreRx through selected CVS Pharmacies commencing March 2nd. To verify which CVS stores will initially carry SnoreRx, go to: www.snorerx.com. Production is being expanded and is working 24/7 to meet market demand; we hope to have SnoreRx available to all consumers by year end."
Apnea Sciences Corporation's mission is to develop Best in Class products like SnoreRx that treat real health problems - like snoring. Restoring the health and vitality to people's lives is what drives their success. Apnea Sciences Corporation is a registered FDA medical device company Certified by ISO, FDA, CAMD and CE. Its primary focus is sleep related products that treat snoring and sleep apnea.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.